MSB

3.21%

$1.13 mesoblast limited

banter and General Discussion, page-10279

First 10279 Last

Share
Profile

Follow
Artephius

463 Posts.

142

18/07/24

21:34

Post #: 74819667
Share

Originally posted by csrwin: ↑

GOVERNMENT INTERESTGOVERNMENT SUPPORT CLAUSE [0002] This invention was made with government support under Grant No. EEC-1648035 from the National Science Foundation and Grant Number AR062368 from the National Institutes of Health. The government has certain rights in the invention.BACKGROUND[0003] Bone-marrow derived human mesenchymal stromal cells (hMSCs), also termed mesenchymal stem cells, represent a promising cell therapy candidate for their anti-inflammatory and immunomodulatory properties. Despite almost three decades of clinical development for diverse inflammatory and immune disease indications (Pittenger 2019) no hMSC product has yet to reach the US market. Whereas early phase hMSC clinical research had promising results, setbacks were faced at advanced clinical phases as endpoints failed to be met (Levy 2020; Martin 2019; Wechsler 2021). For example, the multicenter Prochymal? phase III clinical trial (Osiris Therapeutics Inc., now Mesoblast Inc., NCT00366145) of hMSC treatment for steroid-resistant graft-versus-host disease had disappointing outcomes despite promising early phase results (Galipeau 2013). More recently, the US Food and Drug Administration (US FDA) rejected a biological license application (BLA 125706, August 2020) by Mesoblast for a similar hMSC product due to the inability to show defined potency attributes representative of in vivo or clinical performance and resulting lack of assurance in consistent manufacturing processes (FDA 2020).

Blah Blah Blah!!!
[0123] Flow cytometry: For cell isolation from microfluidic system, the hydrogels were removed and placed in solution of collagenase I (0.2-0.5%), bovine serum albumin (0.1-0.2%), CaCl.sub.2) (10 mM) dissolved in DI water for 30 minutes of incubation or until complete degradation with light agitation. For flow cytometry, viability staining was performed using Zombie Viability

DATE PUBLISHED 2024-06-27

Expand

Don't quote me. Quote Si. Latest annual report

FETAL BOVINE SERUM

MSB Price at posting: $1.11 Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

There are more pages in this discussion • 791 more messages in this thread...

First 10279 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

banter and General Discussion, page-10279

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

banter and General Discussion, page-10279

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News